Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development
Accure Therapeutics SL
Anvyl LLC
Astellas Pharma Inc
AstraZeneca Plc
Atai Life Sciences AG
Autifony Therapeutics Ltd
Biogen Inc
Boehringer Ingelheim Intertiol GmbH
Bristol-Myers Squibb Co
Coronis NeuroSciences Ltd
EuMentis Therapeutics Inc
F. Hoffmann-La Roche Ltd
Neurocrine Biosciences Inc
Novartis AG
Pfizer Inc
SK Biopharmaceuticals Co Ltd
Sosei Heptares
Spherium Biomed SL
Suven Life Sciences Ltd
Vanda Pharmaceuticals Inc
Cognitive Impairment Associated With Schizophrenia (CIAS) - Drug Profiles
ACT-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-5736 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-3288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
basmisanil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-425809 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-955829 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAD-8688 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAD-9303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EM-036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-9936 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
luvadaxistat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBI-1065846 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-03463275 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RL-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
samelisant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-20540 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Modulate CHRM for Central Nervous System and Respiratory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-14040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVND-4010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VQW-765 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products
Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones
Featured News & Press Releases
Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a “RETOS-Colaboraci?n” grant
Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
Apr 17, 2013: SK Biopharma Announces FDA’s Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS)
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Accure Therapeutics SL, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Anvyl LLC, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Atai Life Sciences AG, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Autifony Therapeutics Ltd, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Biogen Inc, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Boehringer Ingelheim International GmbH, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Co, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by EuMentis Therapeutics Inc, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neurocrine Biosciences Inc, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Novartis AG, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co Ltd, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sosei Heptares, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Suven Life Sciences Ltd, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, 2021
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, 2021 (Contd..1)
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, 2021 (Contd..2)
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, 2021